Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Nemaura Medical, Inc. (NASDAQ: NMRD).

Full DD Report for NMRD

You must become a subscriber to view this report.


Recent News from (NASDAQ: NMRD)

Nemaura Medical to Present at the UBS Global Healthcare Conference
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT ® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Chief Business Officer, Bashir Timol, will be presenting at the UBS Global Heal...
Source: Business Wire
Date: May, 15 2018 09:30
Nemaura Medical Appoints Bashir Timol Chief Business Officer
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, current Director of Strategy & Corporate Development, has been ...
Source: Business Wire
Date: April, 09 2018 09:30
Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has appointed The Ruth Group (TRG), a leading healthcare-focused strategic com...
Source: Business Wire
Date: March, 28 2018 11:05
Nemaura Medical to Ring the Nasdaq Closing Bell
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, Director of Strategy and Corporate Development, will ring the closi...
Source: Business Wire
Date: March, 06 2018 09:00
CORRECTING and REPLACING -- Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell
In a release issued earlier today by Nasdaq, Inc. (Nasdaq:NDAQ) under the headline "Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell," please note Mr. Bashir Timol, Director of Strategy and Corporate Development, will ring the Closing Bell, not Dr. Faz C...
Source: GlobeNewswire
Date: March, 05 2018 10:50
Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, March 05, 2018 (GLOBE NEWSWIRE) -- What:  Nemaura Medical Inc. (Nasdaq:NMRD) will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. Faz Chowdhury, Chef Executive Officer , will ring the Closing Bell.  Where: Nasdaq MarketSite ...
Source: GlobeNewswire
Date: March, 05 2018 10:00
Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has commenced expansion into new manufacturing facilities, enabling large scale pro...
Source: Business Wire
Date: March, 01 2018 16:18
Nemaura Medical reports Q3 results
Nemaura Medical ( OTCQB:NMRD ): Q3 net loss of $0.43M Press Release More news on: Nemaura Medical, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: February, 09 2018 13:34
Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today reported financial results for the third quarter ended December 31, 2017. Recent Highlights a...
Source: Business Wire
Date: February, 09 2018 13:17
Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today announced positive summary data for its sugarBEAT ® European clinical trial program. Th...
Source: Business Wire
Date: January, 31 2018 13:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-183.0153.01963.03013.0155,222
2018-05-173.0153.01963.03013.0155,222

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-133,0157,71939.0595Short
2018-08-095004,90510.1937Cover
2018-08-085002,27921.9394Cover
2018-08-076,90511,27661.2363Short
2018-08-064,50710,11144.5752Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NMRD.


About Nemaura Medical, Inc. (NASDAQ: NMRD)

Logo for Nemaura Medical, Inc. (NASDAQ: NMRD)

Nemaura Medical Inc. OTCQB:NMRD is a medical technology company developing sugarBEAT as a non invasive, affordable and flexible glucose monitoring system for adjunctive use by diabetics. SugarBEAT consists of a disposable skin patch connected to a rechargeable transmitter, with an app displaying glucose readings.

 

 

 

Current Management

  • Dewan F H Chowdhury / CEO
  • Iain Anderson / CFO
  • Karrar Khan / Director, Prod. Dev.
  • David Scott / Director, Comm.
  • Richard Toon / Business Development
  • Salim Natha / NonExecutive Director, Independent Director, Compensation Committee Member
  • Timothy Johnson / Director
  • Thomas Moore / Director
  • Bashir Timol /

Current Share Structure

  • Market Cap: $339,733,520 - 03/16/2018
  • Authorized: 420,000,000 - 02/08/2018
  • Issue and Outstanding: 67,676,000 - 02/08/2018
  • Float: 34,941,010 - 11/17/2017

 


Recent Filings from (NASDAQ: NMRD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 10 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 10 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 02 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: NMRD)

Daily Technical Chart for (NASDAQ: NMRD)


Stay tuned for daily updates and more on (NASDAQ: NMRD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NMRD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NMRD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NMRD and does not buy, sell, or trade any shares of NMRD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/